Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial-Reference-Cited by-全球学者库

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Published:2018-03-01 Issue:3 Volume:4 Page:302
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Gianni Luca¹,Mansutti Mauro²,Anton Antonio³,Calvo Lourdes⁴,Bisagni Giancarlo⁵,Bermejo Begoña⁶,Semiglazov Vladimir⁷,Thill Marc⁸,Chacon Jose Ignacio⁹,Chan Arlene¹⁰,Morales Serafin¹¹,Alvarez Isabel¹²,Plazaola Arrate¹³,Zambetti Milvia¹,Redfern Andrew D.¹⁴,Dittrich Christian¹⁵,Dent Rebecca Alexandra¹⁶,Magazzù Domenico¹⁷,De Fato Raffaella¹⁷,Valagussa Pinuccia¹⁷,Tusquets Ignacio¹⁸

Affiliation:

1. Department of Medical Oncology, San Raffaele Scientific Institute, Milano, Italy

2. Department of Oncology, Azienda Sanitaria Universitaria Integrata, Udine, Italy

3. Department of Medical Oncology, Miguel Servet University Hospital, Aragón Health Research Institute, Zaragoza, Spain

4. Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

5. IRCCS Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy

6. Department of Medical Oncology, Hospital Clinico Universitario Valencia, Valencia, Spain

7. NN Petrov Research Institute of Oncology, St Petersburg, Russia

8. Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Germany

9. Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain

10. Breast Cancer Research Centre, Western Australia & Curtin University, Perth, Australia

11. Department of Medical Oncology, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain

12. Department of Oncology, Hospital Universitario Donostia, San Sebastian, Spain

13. Onkologikoa, Hospital Donostia, San Sebastián, Spain

14. Department of Medical Oncology, Royal Perth Hospital, Perth, Australia

15. Applied Cancer Research–Institution for Translational Research Vienna (ACR-ITR VIEnna) & Kaiser Franz Josef-Spital, Vienna, Austria

16. Department of Medical Oncology, National Cancer Center Singapore, Singapore

17. Fondazione Michelangelo, Milano, Italy

18. Department of Medical Oncology, Hospital del Mar, Barcelona, Spain

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma;Radiotherapy and Oncology;2024-02

2. The tumor microenvironment: a key player in multidrug resistance in cancer;Oncologie;2024-01-01

3. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis;BMC Cancer;2023-08-23

4. Red blood cells: a potential delivery system;Journal of Nanobiotechnology;2023-08-22

5. Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer;Japanese Journal of Clinical Oncology;2023-08-22